SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 11, 2019
Principia Biopharma Inc.
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
|(Commission File Number)|| |
220 East Grand Avenue,
South San Francisco, California
|(Address of Principal Executive Offices)||(Zip Code)|
Registrants Telephone Number, Including Area Code: (650) 416-7700
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 1.02|| |
Termination of a Material Definitive Agreement
Principia Biopharma Inc. (the Company) issued a press release on March 11, 2019 announcing a mutual agreement with AbbVie Biotechnology Limited (AbbVie) to end their collaboration under the Development and License Agreement dated as of June 9, 2017 between the Company and AbbVie (the AbbVie Agreement). Under the AbbVie Agreement, the Company and AbbVie collaborated on the research and preclinical development of oral immunoproteasome inhibitors, with each company bearing its own costs. Under the AbbVie Agreement, the Company had the potential to receive additional development, regulatory and commercial milestones of up to an aggregate of $667.5 million, as well as tiered royalties in the high single digits. The two companies concluded the collaboration effective March 8, 2019. The Company has now reacquired all rights and intellectual property from the collaboration and there are no further financial obligations of either party.
The foregoing description of the AbbVie Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which was filed as Exhibit 10.12 to Form S-1/A on September 13, 2018 and is incorporated herein by reference.
A copy of this press release is attached hereto as Exhibit 99.1.
|Item 9.01|| |
Financial Statements and Exhibits.
|99.1||Press Release issued by Principia Biopharma Inc. dated March 11, 2019.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|Date: March 13, 2019||By:|
|Christopher Y. Chai|
|Chief Financial Officer|
Principia Biopharma Reacquires Rights to Oral
Principia and AbbVie mutually agree to end collaboration
Preclinical stage program focused on development of oral immunoproteasome inhibitors to
treat inflammation and autoimmune disorders
SOUTH SAN FRANCISCO, Calif., March 11, 2019 Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, announced a mutual agreement with AbbVie Biotechnology Limited (AbbVie) to end their collaboration aimed at developing oral immunoproteasome inhibitors and for Principia to reacquire the rights to the program. The two companies have agreed to conclude the collaboration effective March 2019.
AbbVie has completed an initial evaluation of Principias highly selective, orally bioavailable covalent inhibitors of the immunoproteasome and, after an assessment of their biologic profiles relative to AbbVies desired disease areas of focus, has determined that there is no longer a strategic fit, said Martin Babler, Chief Executive Officer of Principia. Re-acquiring these rights will allow us to pursue multiple opportunities to treat inflammation and autoimmune disorders through selective immunoproteasome inhibition.
We are grateful for AbbVies support and contributions in what was a highly productive and collaborative relationship resulting in the discovery of new biology, said David Goldstein, Ph.D., Chief Scientific Officer of Principia. With the program in advanced lead optimization, regaining worldwide rights provides Principia with the opportunity to capture the full value of the program and to select the optimal development path for these highly differentiated assets.
Principia Biopharma and AbbVie initiated their collaboration in 2017 to jointly research and develop selective oral immunoproteasome inhibitors to target autoimmunity. Since 2017, both AbbVie and Principia have contributed to the programs overall knowledge base, discovering new science with Principias highly specific molecules, and advancing into later stages of preclinical lead optimization. Principia has now reacquired all rights and intellectual property from the collaboration and there are no further financial obligations of either party.
About Principia Biopharma
Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principias proprietary Tailored Covalency® platform enables Principia to design and develop reversible and irreversible covalent, small molecule inhibitors with potencies and selectivities that have the potential to rival those of injectable biologics yet maintain the convenience of a pill. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 3 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in a Phase 2 clinical trial in patients with immune thrombocytopenic purpura, a rare hematological disease. PRN2246, a covalent BTK inhibitor which crosses the blood-brain barrier, has completed a Phase 1 clinical trial in healthy volunteers, and has been partnered with Sanofi for development in multiple sclerosis and, potentially, for other diseases of the central nervous system. PRN1371, a covalent inhibitor of Fibroblast Growth Factor Receptor (FGFR) is being evaluated in a Phase 1 trial in patients with bladder cancer. For more information, please visit www.principiabio.com.
This press release contains forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Principias expectations regarding the Principia pipeline of product candidates, the potential future development of our oral immunoproteasome inhibitors, and the potential of our oral immunoproteasome inhibitors to treat inflammatory and autoimmune disorders.
Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Principias actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the clinical development process and of clinical trial recruitment; risks and uncertainties about the efficacy, safety and tolerability of our product candidates; risks that early research or clinical results may be materially different from future clinical results; risks and uncertainties regarding Principias reliance on third-party organizations, such as contract research organizations, contract manufacturing organizations, and partners such as Sanofi; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Principias patents or proprietary rights; and the risk that Principias proprietary rights may be insufficient to protect its technologies and product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Principias business in general, see the risk factors set forth in Principias reports filed with the Securities and Exchange Commission, including its Quarterly report on form 10-Q for the period ending September 30, 2018. Any forward-looking statements contained in this press release speak only as of the date hereof, and Principia specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Christopher Chai, CFO